Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Women living with cancer feel stigmatized, says new report

Highlights need for increased education, awareness and support

- PMLiVE

Lucid Group start the countdown to its big move

One month to go until Lucid Group moves into their new London Headquarters

Lucid Group Communications Limited

HCP insights_ What about me?

Four Health Wins at the PM Society Digital Awards

A very successful evening at the PM Society Digital Awards last night for the Four Health team! We brought home three Golds, one Silver and one Bronze making us the...

Four Agency Worldwide

- PMLiVE

Abeona Therapeutics’ rare disease phase 3 trial halted due to FDA concerns

Issues over transport stability must be resolved, says regulator

Richard Oakham

Growth and innovation in design and digital tech at Porterhouse

Porterhouse Medical Group is delighted to announce that Richard Oakham has been promoted to the role of Creative Director.Since joining our agency, Richard has made a very positive impact to...

Porterhouse Medical Group

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

Servier faces manslaughter trial over weight loss drug deaths

Drug shown to damage heart and thought to cause death

- PMLiVE

Want to know if you’re dehydrated? There’s an app for that.

Water water everywhere..but are we drinking it?

Page & Page Health

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

Labour party plans to abolish NHS prescription charges

Comes amid increased focus on drug pricing in the US

- PMLiVE

European biotech: a new generation of leaders emerges

Three companies that are on the rise in biotech

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links